Cargando…

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults

Side effect profiles of antidepressants are relevant to treatment selection and adherence among patients with major depressive disorder (MDD), but several clinically-relevant characteristics of side effects are poorly understood. We aimed to compare the side effect profiles of escitalopram and dulox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polychroniou, Philip E., Mayberg, Helen S., Craighead, W. Edward, Rakofsky, Jeffrey J., Aponte Rivera, Vivianne, Haroon, Ebrahim, Dunlop, Boadie W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071033/ https://www.ncbi.nlm.nih.gov/pubmed/30018196 http://dx.doi.org/10.3390/bs8070064

Ejemplares similares

Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
por: Tai, Hua-Hsin, et al.
Publicado: (2021)

Neuroimaging-based biomarkers for treatment selection in major depressive disorder
por: Dunlop, Boadie W., et al.
Publicado: (2014)

Neuroimaging Advances for Depression
por: Dunlop, Boadie W., et al.
Publicado: (2017)

A Virtual Standardized Patient–Based Assessment Tool to Evaluate Psychiatric Residents’ Psychopharmacology Proficiency
por: Rakofsky, Jeffrey J., et al.
Publicado: (2020)

The United States index of socioeconomic deprivation for individuals (USiDep)
por: Dunlop, Boadie W., et al.
Publicado: (2022)

Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
por: Dunlop, Boadie W, et al.
Publicado: (2012)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
por: Miller, Christopher W. T., et al.
Publicado: (2016)

Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine – a quantitative EEG study in rats
por: Leiser, S C, et al.
Publicado: (2014)

Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
por: Brydges, Christopher R., et al.
Publicado: (2021)

Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
por: Dunlop, Boadie W.
Publicado: (2020)

Unilateral Galactorrhea Associated with Low-dose Escitalopram
por: Ravi, P. Bangalore, et al.
Publicado: (2014)

The effect of a single dose of escitalopram on sensorimotor networks
por: Weisstanner, Christian, et al.
Publicado: (2018)

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada, Eiji, et al.
Publicado: (2015)

Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy
por: Espinola, Caroline W., et al.
Publicado: (2022)

Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method
por: Liu, Xin, et al.
Publicado: (2023)

Escitalopram induced mania
por: Parker, Shubangi, et al.
Publicado: (2007)

Escitalopram in patients with psoriasis
por: Artemieva, M., et al.
Publicado: (2021)

Escitalopram Induced Angioedema
por: Conde, Samantha L, et al.
Publicado: (2022)

Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second‐generation antidepressants: Study protocol for a randomized, parallel‐group, non‐inferiority trial
por: Yokoi, Yuma, et al.
Publicado: (2019)

Mydriasis caused by ESCITALOPRAM: Case report
por: Bouattour, N., et al.
Publicado: (2022)

Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder
por: Dunlop, Boadie W., et al.
Publicado: (2018)

Duloxetine hydrochloride
por: Bhadbhade, Mohan, et al.
Publicado: (2009)

Duloxetine induced hyponatremia
por: Kulkarni, M.
Publicado: (2015)

Short-term escitalopram treatment and hippocampal volume
por: Godlewska, Beata R., et al.
Publicado: (2014)

Acute Dystonia after Using Single Dose Duloxetine: Case Report
por: Karakaş Uğurlu, Görkem, et al.
Publicado: (2013)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
por: Rodrigues-Amorim, Daniela, et al.
Publicado: (2020)

Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings
por: Dunlop, Boadie W., et al.
Publicado: (2017)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Different Endocrine Effects of an Evening Dose of Amitriptyline, Escitalopram, and Placebo in Healthy Participants
por: Frase, Lukas, et al.
Publicado: (2018)

Mydriasis caused by ESCITALOPRAM: A case report
por: Bouattour, N., et al.
Publicado: (2023)

Interaction between escitalopram and risperidone
por: Rao, Pradeep, et al.
Publicado: (2005)

Severe hyponatremia associated with escitalopram
por: Rawal, Gautam, et al.
Publicado: (2017)

Escitalopram-induced extrapyramidal symptoms
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2019)

Rise of escitalopram and the fall of citalopram
por: Cavanah, Luke R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jfv90q2msdj3kmdi6h3nctps8v